These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28223694)

  • 21. Enhanced delivery of the RAPTA-C macromolecular chemotherapeutic by conjugation to degradable polymeric micelles.
    Blunden BM; Lu H; Stenzel MH
    Biomacromolecules; 2013 Dec; 14(12):4177-88. PubMed ID: 24266669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C.
    Ratanaphan A; Temboot P; Dyson PJ
    Chem Biodivers; 2010 May; 7(5):1290-302. PubMed ID: 20491084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer Organometallic Osmium(II)-p-cymene Complexes.
    Păunescu E; Nowak-Sliwinska P; Clavel CM; Scopelliti R; Griffioen AW; Dyson PJ
    ChemMedChem; 2015 Sep; 10(9):1539-47. PubMed ID: 26190176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
    Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
    J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].
    Scolaro C; Hartinger CG; Allardyce CS; Keppler BK; Dyson PJ
    J Inorg Biochem; 2008 Sep; 102(9):1743-8. PubMed ID: 18582946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
    Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
    J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates.
    Renfrew AK; Karges J; Scopelliti R; Bobbink FD; Nowak-Sliwinska P; Gasser G; Dyson PJ
    Chembiochem; 2019 Nov; 20(22):2876-2882. PubMed ID: 31102568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
    Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
    Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
    Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)].
    Chakree K; Ovatlarnporn C; Dyson PJ; Ratanaphan A
    Int J Mol Sci; 2012 Oct; 13(10):13183-202. PubMed ID: 23202946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel dual-functioning ruthenium(II)-arene complex of an anti-microbial ciprofloxacin derivative - Anti-proliferative and anti-microbial activity.
    Ude Z; Romero-Canelón I; Twamley B; Fitzgerald Hughes D; Sadler PJ; Marmion CJ
    J Inorg Biochem; 2016 Jul; 160():210-7. PubMed ID: 26993079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of luminescent ruthenium(II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling.
    Sun D; Liu Y; Yu Q; Zhou Y; Zhang R; Chen X; Hong A; Liu J
    Biomaterials; 2013 Jan; 34(1):171-80. PubMed ID: 23059005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAPTA-Decorated Polyacrylamide Nanoparticles: Exploring their Synthesis, Physical Properties and Effect on Cell Viability.
    Sandland J; Savoie H; Boyle RW; Murray BS
    Chembiochem; 2021 Mar; 22(5):931-936. PubMed ID: 33095468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Half-sandwich Ru(η
    Huang YC; Haribabu J; Chien CM; Sabapathi G; Chou CK; Karvembu R; Venuvanalingam P; Ching WM; Tsai ML; Hsu SCN
    J Inorg Biochem; 2019 May; 194():74-84. PubMed ID: 30831392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents.
    Biancalana L; Pampaloni G; Marchetti F
    Chimia (Aarau); 2017 Sep; 71(9):573-579. PubMed ID: 30188287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
    Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
    Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
    Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
    J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
    Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
    J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.